BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Metabolism of xenobiotics
,
Obesity
,
Hypothalamus
,
Metabolism of nitric oxide
,
FXYD4
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
RNA-binding domain, S1
(biogroup)
Summary
General Info
Body Atlas
Most Correlated Tissues
Kidney medulla
Trachea
Small intestine
Microglial cell
Bronchus
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Rhinitis
Vesicular stomatitis Indiana virus disease
Abscess
Infestation by Sarcoptes scabiei var canis
IgE-mediated allergic disorder
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
IL28A protein, human
Antigens, Neoplasm
sodium bichromate
mosapride
senkirkine
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
bgcn
TCFL5
POLH
NRF1
ife-2
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
The Immunological Genome Project - Immune cell lineage differentiation and maturation
Embryonic stem J1 cells expressing Mettl3 or Mettl14 shRNA
Regulatory and helper T cells following activation with anti-CD3 and anti-CD28
Pediatric medulloblastoma mouse models
Genome-wide transcriptional effects of Pregnancy-Induced Non-coding RNA (PINC)
Explore Curated Studies Results
Literature
Most Relevant Literature
There were no matches for RNA-binding domain, S1
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19
Waxing and Waning of Serum SARS CoV-2-IgG Level in COVID-19 Exposed Population
Antibody Responses in Contacts of COVID-19 Patients
Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)
Immunocompromised Swiss Cohorts Based Trial Platform
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ